Analysing the Evolution of LDL-C Management: A Review of Emerging Data at the ACC
This IME peer-to-peer discussion took place at the American College of Cardiology (ACC) Congress and focused on emerging data in dyslipidaemia, with particular emphasis on PCSK9 inhibition. Centred on findings from the PURSUIT trial, the programme explored the evolving role of PCSK9 therapies and their potential impact on lipid management strategies.
Dr Michael Koren (Florida, US), principal investigator of the PURSUIT trial, was joined by Dr Neha Pagidipati (North Carolina, US) to lead the discussion. Together, they examined the treatment landscape for hypercholesterolaemia, highlighted key clinical trial data, and interpreted the positioning of PCSK9 inhibitors within clinical guidelines and real-world settings.
The discussion provides an overview of hypercholesterolaemia treatments in 2025, followed by a session on PCSK9 inhibitors in guidelines and clinical practice, and concluded with an update on oral PCSK9 inhibitor data.
This peer exchange provides clinicians with practical, evidence-based insights to support personalised lipid-lowering strategies and informed clinical decision-making in an evolving therapeutic landscape.
Key Learning Objectives
- Describe the current landscape of hypercholesterolaemia treatments, including the role of PCSK9 inhibitors and the barriers to their use
- Summarise recent clinical trial data on oral PCSK9 inhibitors and ongoing/future studies
- Discuss the positioning of PCSK9 inhibitors in treatment guidelines and real-world clinical practice, considering patient risk profiles and LDL-C targets
- Evaluate the potential impact of oral PCSK9 inhibitors on clinical decision-making and lipid management strategies
Target Audience
- Cardiologists
- Primary Care Specialist
More from this programme
Part 1
Where are we in 2025 with dyslipidaemia treatments?
Part 2
PCSK9 inhibitors in guidelines and real-world implementation
Part 3
Oral PCSK9 inhibitors: Clinical Data from ACC 2025
Faculty Biographies
Michael J Koren
Michael Koren is a practising cardiologist and Chief Executive Officer at Jacksonville Center for Clinical Research, overseeing clinical trials across eight sites in Florida. He earned his medical degree cum laude from Harvard Medical School and completed his residency in internal medicine and fellowship in cardiology at NewYork Hospital/Memorial Sloan-Kettering Cancer Center/Cornell Medical Center.
A fellow of the American College of Cardiology, Dr Koren also serves as president of the Academy of Physicians in Clinical Research and leads the regional chapter of the American Heart Association. As principal investigator, he has conducted over 500 clinical trials in hypercholesterolaemia, cardiovascular disease and heart failure.
His research has been published in The Lancet, New England Journal of Medicine, Circulation and Journal of the American College of Cardiology. He sits on the editorial board of
Neha Pagidipati
Assistant Professor of Medicine
Neha J Pagidipati is an Assistant Professor of Medicine and cardiovascular disease prevention specialist. Since 2011, she has conducted research on cardiometabolic disease prevention, lifestyle modification and weight management. She is currently an NIH K12 scholar in Implementation and Dissemination Science.
Dr Pagidipati is building the Duke Cardiometabolic Disease Prevention Program, which focuses on behavior change and risk factor management in patients with high risk of cardiovascular and metabolic diseases such as diabetes and obesity.
Dr Pagidipati’s research grants include the COORDINATE-Diabetes Trial, to improve the quality of care for patients with diabetes and cardiovascular disease across the US, and QuBBD: Deep Poisson Methods for Biomedical Time-to-Event and Longitudinal Data.
In addition, she is leading a large study within the Duke Health System to study heterogeneity within cardiovascular disease risk and…
Comments